The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.
The UK Government has failed to convince UK Supreme Court judges that Servier Laboratories misrepresented its blood pressure drugs patent in legal proceedings to block generic competitors from entering the market.
A Warrington-based distributor of aesthetic and cosmetic products has lost its UK trademark for a dermal filler brand after the English High Court found it to have registered the brand in bad faith.
The European Union has submitted a new proposal to the World Trade Organisation, which backs compulsory licensing agreements for COVID-19 vaccines when negotiations fail.
Munich-based firm Bardehle Pagenberg has established a life sciences practice at its Paris office with two recent hires.
The University of California Berkeley has lost a CRISPR patent in Europe in the latest twist in the long-running IP saga over the gene-editing technology.
UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.
The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation by business leaders, academics, economists and trade unions.
The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.